{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:09:20Z","timestamp":1790975360964,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Research Foundation of Korea Grant funded by the Korean Government","award":["NRF-RS-2023-00210922"],"award-info":[{"award-number":["NRF-RS-2023-00210922"]}]},{"name":"The Ministry of Education of the Republic of Korea and the National Research Foundation of Korea","award":["NRF-2020R1AC2005091"],"award-info":[{"award-number":["NRF-2020R1AC2005091"]}]},{"name":"National Cancer Center Grants, Republic of Korea","award":["NCC2310622-3"],"award-info":[{"award-number":["NCC2310622-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid cancer is the most common endocrine malignancy, with an increasing incidence, particularly driven by differentiated thyroid cancers (DTC), including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Although DTC generally have excellent prognosis, dedifferentiated forms such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) exhibit aggressive progression and poor outcomes. Understanding the tumor microenvironment (TME) is crucial for developing novel therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed spatial transcriptomics (ST) on formalin-fixed paraffin-embedded (FFPE) tumor tissues from 12 patients with PTC, FTC, PDTC, or ATC using the Visium CytAssist platform. Cell type composition was inferred using the CellDART algorithm, and pathway activity was assessed via PROGENy and REACTOME analyses. Immunohistochemical (IHC) assays were conducted to validate key TME components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ST analysis revealed significant shifts in cell composition associated with thyroid cancer dedifferentiation. Specifically, there was an increase in myeloid cells and cancer-associated fibroblasts (CAFs), accompanied by a reduction in natural killer (NK) cells and endothelial cells. Intratumoral heterogeneity in the Thyroid Differentiation Score (TDS) showed a strong spatial correlation with myeloid cell density, and among myeloid subtypes, the MDSC score was negatively correlated with TDS. Pathway activity analysis further identified upregulation of the JAK-STAT and VEGF signaling pathways in dedifferentiated tumors, both of which were closely associated with increased myeloid cell infiltration. IHC validation confirmed the differential expression patterns of representative immune and stromal markers across subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that dedifferentiation in thyroid cancer is associated with an immunosuppressive TME that promotes tumor progression. Therapeutic strategies targeting JAK-STAT and VEGF pathways, or enhancing NK cell activity, may hold promises for aggressive thyroid cancers. Further studies with larger cohorts are necessary to validate these findings and develop targeted therapies for aggressive thyroid cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-025-04210-0","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:34:14Z","timestamp":1762144454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor microenvironment remodeling across thyroid cancer differentiation states revealed by spatial transcriptomics"],"prefix":"10.1007","volume":"74","author":[{"given":"Jungirl","family":"Seok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hwan","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsun","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seog Yun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Seog","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"18","key":"4210_CR1","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","volume":"295","author":"L Davies","year":"2006","unstructured":"Davies L (2006) Welch HG increasing incidence of thyroid cancer in the United States, 1973\u20132002. JAMA 295(18):2164\u20132167. https:\/\/doi.org\/10.1001\/jama.295.18.2164","journal-title":"JAMA"},{"issue":"5","key":"4210_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"UC Megwalu","year":"2022","unstructured":"Megwalu UC (2022) Moon PK thyroid cancer incidence and mortality trends in the United States: 2000\u20132018. Thyroid 32(5):560\u2013570. https:\/\/doi.org\/10.1089\/thy.2021.0662","journal-title":"Thyroid"},{"issue":"4344","key":"4210_CR3","doi-asserted-by":"publisher","first-page":"w30029","DOI":"10.4414\/smw.2021.w30029","volume":"151","author":"S Wirth","year":"2021","unstructured":"Wirth S, Syleouni M-E, Karavasiloglou N et al (2021) Incidence and mortality trends of thyroid cancer from 1980 to 2016. Swiss Med Wkly 151(4344):w30029\u2013w30029. https:\/\/doi.org\/10.4414\/smw.2021.w30029","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"4210_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1089\/thy.2019.0415","volume":"30","author":"M Pereira","year":"2020","unstructured":"Pereira M, Williams VL, Hallanger Johnson J et al (2020) Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations. Thyroid 30(8):1132\u20131140. https:\/\/doi.org\/10.1089\/thy.2019.0415","journal-title":"Thyroid"},{"issue":"11","key":"4210_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells JSA (2016) Biologic and clinical perspectives on thyroid cancer. N Engl J Med 375(11):1054\u20131067. https:\/\/doi.org\/10.1056\/NEJMra1501993","journal-title":"N Engl J Med"},{"issue":"9","key":"4210_CR6","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin B, Ma H, Ma M et al (2019) The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 11(9):5888\u20135896","journal-title":"Am J Transl Res"},{"issue":"1","key":"4210_CR7","doi-asserted-by":"publisher","first-page":"542358","DOI":"10.1155\/2011\/542358","volume":"2011","author":"G Nagaiah","year":"2011","unstructured":"Nagaiah G, Hossain A, Mooney CJ et al (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011(1):542358. https:\/\/doi.org\/10.1155\/2011\/542358","journal-title":"J Oncol"},{"issue":"31","key":"4210_CR8","doi-asserted-by":"publisher","first-page":"eabf3657","DOI":"10.1126\/sciadv.abf3657","volume":"7","author":"H Luo","year":"2021","unstructured":"Luo H, Xia X, Kim GD et al (2021) Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv 7(31):eabf3657. https:\/\/doi.org\/10.1126\/sciadv.abf3657","journal-title":"Sci Adv"},{"key":"4210_CR9","doi-asserted-by":"publisher","first-page":"111491","DOI":"10.1016\/j.mce.2021.111491","volume":"541","author":"M Tarabichi","year":"2022","unstructured":"Tarabichi M, Demetter P, Craciun L et al (2022) Thyroid cancer under the scope of emerging technologies. Mol Cell Endocrinol 541:111491. https:\/\/doi.org\/10.1016\/j.mce.2021.111491","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"4210_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13044-020-00091-w","volume":"13","author":"S De Leo","year":"2020","unstructured":"De Leo S, Trevisan M (2020) Fugazzola L recent advances in the management of anaplastic thyroid cancer. Thyroid Res 13(1):17. https:\/\/doi.org\/10.1186\/s13044-020-00091-w","journal-title":"Thyroid Res"},{"issue":"1","key":"4210_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P (2018) Theis FJ SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19(1):15. https:\/\/doi.org\/10.1186\/s13059-017-1382-0","journal-title":"Genome Biol"},{"issue":"10","key":"4210_CR12","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1093\/nar\/gkac084","volume":"50","author":"S Bae","year":"2022","unstructured":"Bae S, Na KJ, Koh J et al (2022) Celldart: cell type inference by domain adaptation of single-cell and spatial transcriptomic data. Nucleic Acids Res 50(10):e57. https:\/\/doi.org\/10.1093\/nar\/gkac084","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"4210_CR13","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1158\/1538-7445.AM2023-3131","volume":"83","author":"L Lu","year":"2023","unstructured":"Lu L, Wang JR, Henderson YC et al (2023) Anaplastic transformation model in thyroid cancer revealed by single cell lineage and fate analysis. Cancer Res 83(7):3131\u20133131","journal-title":"Cancer Res"},{"issue":"5","key":"4210_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41587-020-00795-2","volume":"39","author":"R Gao","year":"2021","unstructured":"Gao R, Bai S, Henderson YC et al (2021) Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol 39(5):599\u2013608. https:\/\/doi.org\/10.1038\/s41587-020-00795-2","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4210_CR15","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"J V\u00e9lez Santiago","year":"2022","unstructured":"V\u00e9lez Santiago J, Braunger J et al (2022) decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinformat Adv 2(1):vbac016","journal-title":"Bioinformat Adv"},{"issue":"1","key":"4210_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, Klinger B, Kl\u00fcnemann M et al (2018) Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun 9(1):20. https:\/\/doi.org\/10.1038\/s41467-017-02391-6","journal-title":"Nat Commun"},{"issue":"12","key":"4210_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R et al (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27(12):1739\u20131740. https:\/\/doi.org\/10.1093\/bioinformatics\/btr260","journal-title":"Bioinformatics"},{"issue":"5","key":"4210_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M (2021) MDSC: markers, development, states, and unaddressed complexity. Immunity 54(5):875\u2013884. https:\/\/doi.org\/10.1016\/j.immuni.2021.04.004","journal-title":"Immunity"},{"issue":"9","key":"4210_CR19","doi-asserted-by":"publisher","first-page":"e2100041","DOI":"10.1002\/biot.202100041","volume":"16","author":"N Wang","year":"2021","unstructured":"Wang N, Li X, Wang R et al (2021) Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment. Biotechnol J 16(9):e2100041. https:\/\/doi.org\/10.1002\/biot.202100041","journal-title":"Biotechnol J"},{"key":"4210_CR20","doi-asserted-by":"publisher","first-page":"875384","DOI":"10.3389\/fphar.2022.875384","volume":"13","author":"Q Liu","year":"2022","unstructured":"Liu Q, Sun W, Zhang H (2022) Roles and new insights of macrophages in the tumor microenvironment of thyroid cancer. Front Pharmacol 13:875384. https:\/\/doi.org\/10.3389\/fphar.2022.875384","journal-title":"Front Pharmacol"},{"key":"4210_CR21","doi-asserted-by":"publisher","first-page":"637826","DOI":"10.3389\/fendo.2020.637826","volume":"11","author":"E Menicali","year":"2020","unstructured":"Menicali E, Guzzetti M, Morelli S et al (2020) Immune landscape of thyroid cancers: new insights. Front Endocrinol 11:637826. https:\/\/doi.org\/10.3389\/fendo.2020.637826","journal-title":"Front Endocrinol"},{"issue":"4","key":"4210_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1677\/ERC-08-0036","volume":"15","author":"M Ryder","year":"2008","unstructured":"Ryder M, Ghossein RA, Ricarte-Filho JC et al (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15(4):1069\u20131074. https:\/\/doi.org\/10.1677\/ERC-08-0036","journal-title":"Endocr Relat Cancer"},{"issue":"40","key":"4210_CR23","doi-asserted-by":"publisher","first-page":"eaaw9159","DOI":"10.1126\/sciimmunol.aaw9159","volume":"4","author":"Y Si","year":"2019","unstructured":"Si Y, Merz SF, Jansen P et al (2019) Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue. Sci Immunol 4(40):eaaw9159. https:\/\/doi.org\/10.1126\/sciimmunol.aaw9159","journal-title":"Sci Immunol"},{"issue":"4","key":"4210_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3803\/EnM.2020.401","volume":"35","author":"L Fozzatti","year":"2020","unstructured":"Fozzatti L, Cheng S-Y (2020) Tumor cells and cancer-associated fibroblasts: a synergistic crosstalk to promote thyroid cancer. Endocrinol Metab (Seoul) 35(4):673\u2013680. https:\/\/doi.org\/10.3803\/EnM.2020.401","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"4210_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3803\/EnM.2019.34.2.132","volume":"34","author":"EK Lee","year":"2019","unstructured":"Lee EK, Sunwoo JB (2019) Natural killer cells and thyroid diseases. Endocrinol Metab (Seoul) 34(2):132\u2013137. https:\/\/doi.org\/10.3803\/EnM.2019.34.2.132","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"4210_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081904","volume":"13","author":"SA Lim","year":"2021","unstructured":"Lim SA, Moon Y, Shin MH et al (2021) Hypoxia-driven HIF-1\u03b1 activation reprograms pre-activated NK cells towards highly potent effector phenotypes via ERK\/STAT3 pathways. Cancers 13(8):1904. https:\/\/doi.org\/10.3390\/cancers13081904","journal-title":"Cancers"},{"key":"4210_CR27","first-page":"007","volume":"1","author":"A Jewett","year":"2012","unstructured":"Jewett A, Nakamura H, Wang M et al (2012) Dedifferentiation of epithelial tumors enhances citotoxicity, survival, and expansion of allogenic CD8+ T cells and natural killer cells. J Carcinogen Mutagen 1:007","journal-title":"J Carcinogen Mutagen"},{"key":"4210_CR28","doi-asserted-by":"publisher","first-page":"1414450","DOI":"10.3389\/fimmu.2024.1414450","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Li X, Yang B et al (2024) Deciphering breast cancer prognosis: a novel machine learning-driven model for vascular mimicry signature prediction. Front Immunol 15:1414450. https:\/\/doi.org\/10.3389\/fimmu.2024.1414450","journal-title":"Front Immunol"},{"key":"4210_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara M, Kiyota N, Yamazaki T et al (2017) Lenvatinib for anaplastic thyroid cancer. Front Oncol 7:25. https:\/\/doi.org\/10.3389\/fonc.2017.00025","journal-title":"Front Oncol"},{"key":"4210_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.20517\/2394-4722.2020.58","volume":"6","author":"Z Qureshy","year":"2020","unstructured":"Qureshy Z, Johnson DE (2020) Grandis JR Targeting the JAK\/STAT pathway in solid tumors. J Cancer Metastasis Treat 6:27. https:\/\/doi.org\/10.20517\/2394-4722.2020.58","journal-title":"J Cancer Metastasis Treat"},{"issue":"5","key":"4210_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/1541-7786.MCR-21-0832","volume":"21","author":"J Limberg","year":"2023","unstructured":"Limberg J, Egan CE, Gray KD et al (2023) Activation of the JAK\/STAT pathway leads to BRAF inhibitor resistance in BRAFV600E positive thyroid carcinoma. Mol Cancer Res 21(5):397\u2013410. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0832","journal-title":"Mol Cancer Res"},{"issue":"12","key":"4210_CR32","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s00262-023-03549-6","volume":"72","author":"L Zhu","year":"2023","unstructured":"Zhu L, Li XJ, Gangadaran P et al (2023) Tumor-associated macrophages as a potential therapeutic target in thyroid cancers. Cancer Immunol Immunother 72(12):3895\u20133917. https:\/\/doi.org\/10.1007\/s00262-023-03549-6","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04210-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:37Z","timestamp":1764600337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4210"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04210-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to a prospective registry and was conducted with patients\u2019 informed consent, approved by the Institutional Review Board of the National Cancer Center (IRB No. NCC2014-0003). The study protocol was reviewed and approved for the secondary utilization of previously consented human-derived material (IRB No. NCC2023-0102).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is obtained for all patients in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"357"}}